liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
University of Helsinki, Finland; Helsinki University Hospital, Finland.
University of Helsinki, Finland; Helsinki University Hospital, Finland.
University of Helsinki, Finland; Helsinki University Hospital, Finland.
University of Helsinki, Finland; Helsinki University Hospital, Finland.
Show others and affiliations
2017 (English)In: Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, E-ISSN 1432-1335, Vol. 143, no 8, 1543-1554 p.Article in journal (Refereed) Published
Abstract [en]

Purpose Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied TKI-induced changes in B cell-mediated immunity. Methods We collected peripheral blood (PB) and bone marrow (BM) samples from chronic myeloid leukemia (CML) patients before and during first-line imatinib (n = 20), dasatinib (n = 16), nilotinib (n = 8), and bosutinib (n = 12) treatment. Plasma immunoglobulin levels were measured, and different B cell populations in PB and BM were analyzed with flow cytometry. Results Imatinib treatment decreased plasma IgA and IgG levels, while dasatinib reduced IgM levels. At diagnosis, the proportion of patients with IgA, IgG, and IgM levels below the lower limit of normal (LLN) was 0, 11, and 6% of all CML patients, respectively, whereas at 12 months timepoint the proportions were 6% (p = 0.13), 31% (p = 0.042) and 28% (p = 0.0078). Lower initial Ig levels predisposed to the development of hypogammaglobulinemia during TKI therapy. Decreased Ig levels in imatinibtreated patients were associated with higher percentages of immature BM B cells. The patients, who had low Ig levels during the TKI therapy, had significantly more frequent minor infections during the follow-up compared with the patients with normal Ig values (33% vs. 3%, p = 0.0016). No severe infections were reported, except recurrent upper respiratory tract infections in one imatinib-treated patient, who developed severe hypogammaglobulinemia. Conclusions TKI treatment decreases plasma Ig levels, which should be measured in patients with recurrent infections.

Place, publisher, year, edition, pages
Springer, 2017. Vol. 143, no 8, 1543-1554 p.
Keyword [en]
CML; Tyrosine kinase inhibitor; B cell; Immunoglobulin
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-139536DOI: 10.1007/s00432-017-2378-6ISI: 000405312900015PubMedID: 28337541Scopus ID: 2-s2.0-85015969804OAI: oai:DiVA.org:liu-139536DiVA: diva2:1130072
Note

Funding Agencies|Academy of Finland; Finnish Cancer Societies; Sigrid Juselius Foundation; Finnish Cancer Institute; Signe and Ane Gyllenberg Foundation; Otto A. Malm Foundation; EUTOS project for CML; Pfizer; Novartis; Bristol-Myers Squibb [NordCML006, NordCML007]

Available from: 2017-08-08 Created: 2017-08-08 Last updated: 2017-08-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Lotfi, Kourosh
By organisation
Department of Clinical and Experimental MedicineFaculty of Medicine and Health SciencesDepartment of Haematology
In the same journal
Journal of Cancer Research and Clinical Oncology
Hematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 41 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf